ArticleInfection and drug resistance2018
Synergy effect of meropenem-based combinations against
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pharmacokinetic-pharmacodynamic modeling using combined time-kill data for meropenem and colistin or polymyxin B combination effects inAntimicrobial agents and chemotherapy · 2026Pooled it
- Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Mathematical modelling of synergistic triple-antibiotic therapy against carbapenem-resistantJournal of medical microbiology · 2025Article
- Nanomedicine approaches to enhance the effectiveness of meropenem: a strategy to tackle antimicrobial resistance.Discover nano · 2025Review
- Combinations of Antibiotics Effective against Extensively- and Pandrug-ResistantMicroorganisms · 2024Article
- Genomic Insights into and In Vitro Evaluation of Antimicrobial Combination Therapies for Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2024Article
- In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates.European journal of medical research · 2024Article
- Unsupervised learning and natural language processing highlight research trends in a superbug.Frontiers in artificial intelligence · 2024Article
- Mutations inmBio · 2023Article
- In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2022Article
- Growth kinetics of multipleF1000Research · 2022Article
- Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.Drugs in context · 2022Review
- Systematic Review of Antimicrobial Combination Options for Pandrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Article
- A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2020Article
- In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-ResistantMolecules (Basel, Switzerland) · 2019Article
- In vitro activity of colistin in combination with various antimicrobials againstInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe main objective of our meta-analysis was to examine the in vitro synergistic effect of meropenem-based combination therapies against
methodsAn extensive search was performed with no restrictions on date of publication, language, and publication type. Our study evaluated the main conclusions drawn from various studies describing the synergistic activity of combination therapies in vitro.
resultsIn this review, 56 published studies were included. Our report included data on 20 types of antibiotics combined with meropenem in 1,228
conclusionWe found that time-kill studies generally identified the greatest synergy, while checkerboard and Etest methods yielded relatively poor synergy rates. Further well-designed in vivo studies should be carried out to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.